NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...
NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
Project Brainstorm is not your typical science course. Instead of reading a book about the brain the old-fashioned way, UCLA neuroscience students teach local K-12 students hands-on science with ...
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
[ooyala code=”d0Y3FiYTE6fCi7eqUynYTG5J01UqrzJ0″ player_id=”5fd9e8bf3aa4c5abfd6d1a426e5cfe7″ auto=”true” width=”1920″ height=”1080″] There’s bi ...
ParaMind Brainstorming Software releases New Version of its Unique Brainstorming Software Program. ParaMind Brainstorming Software of Seattle, Washington announces the release of their new advanced ...
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results